| Overview |
| bs-13145R-Cy5 |
| FARSLA/CML33 Polyclonal Antibody, Cy5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Cow, Sheep, Pig, Horse |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human FARSLA/CML33 |
| 51-150/508 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 10160 |
| Cytoplasm |
| CML 33; CML33; FARS; FARSA; FARSL; FRSA; PheHA; Phenylalanine tRNA ligase 1 alpha cytoplasmic; Phenylalanine tRNA ligase alpha chain; Phenylalanine tRNA synthetase alpha subunit; Phenylalanine tRNA synthetase like alpha subunit; Phenylalanyl tRNA synthetase alpha chain; Phenylalanyl tRNA synthetase alpha subunit; Phenylalanyl tRNA synthetase like alpha subunit; PheRS. |
| Aminoacyl-tRNA synthetases consist of a family of enzymes that catalyze the specific aminoacylation of tRNA by their cognate amino acid in the initial step of ribosome-dependent protein biosynthesis. FARSLA, also known as FRSA, CML33, FARSL or PheHA (phenylalanyl-tRNA synthetase, alpha subunit), is a member of the class-II aminoacyl-tRNA synthetase family and is highly expressed in proliferating cells of bone marrow. FARSLA is a cytoplasmic phenylalanine-tRNA synthetase that functions as a heterodimer consisting of a catalytic alpha-subunit and a regulatory beta-subunit. The alpha-subunit is responsible for forming the amino acid binding pocket, mediating the ATP/aminoacyl adenylate binding, and interacts with the acceptor stem of the tRNA. FARSLA functions in a cell cycle-dependent and differentiation-dependent manner. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz